Steady is the assessment that comes to mind, rather than remarkable, when probing the year-on-year direction of corporate venture capital investment in university spinouts.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.

Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.

Versant's unusual build-to-buy model has resulted in Roche acquiring a target for MS based on UCSF research and the venture firm launching a new spinout, Pipeline Therapeutics.

Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.